Inve India ▾

Shaily Engineering Plastics share price & results

Shaily Engineering Plastics Limited· Consumer Durables· Consumer Discretionary

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

India's largest plastics-component exporter, making precision injection-moulded parts for global OEMs.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue275 ₹ crore+22.2% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin31.0 %+4.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit52.0 ₹ crore+44.4% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity27.87 %+8.4 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin4.04 %−0.8 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)19.88 %+3.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

3 of 4 judged targets kept · 14 open · verdicts reflect calls analysed to Q1 FY27.

Shaily Engineering Plastics Limited management guidance track record on Inve: 18 targets tracked across analysed earnings calls (3 achieved, 1 missed, 14 open).

TargetOriginal wordingSaidLatest callVerdict
Healthcare Revenue ContributionMedical device business will comprise about 30% of our revenues over the next few years.
Call transcript, Q4 FY25 · 14 May 2025
Q4 FY25Q1 FY27:Healthcare revenue contributed 51% of consolidated revenue for the quarter, continuing to significantly exceed the target.
Call transcript, Q1 FY27 · 10 Aug 2026
Achieved
Pen Sales VolumeSelling close to somewhere between 30 million to 35 million pens this year (FY26).
Call transcript, Q4 FY25 · 14 May 2025
Q4 FY25Q1 FY27:Promise pertains to FY26, which has passed. No update provided on the final FY26 number.
Call transcript, Q1 FY27 · 10 Aug 2026
Ghosted
Semaglutide Pen Capacity AdditionThe additional 25 million that will come in by July, August is purely for Semaglutide.
Call transcript, Q4 FY26 · 20 May 2026
Q4 FY26Q1 FY27:The timeline has been slightly pushed. Management now expects the capacity to be operational by the end of September.
Call transcript, Q1 FY27 · 10 Aug 2026
Delayed

Source: Inve Guidance Tracker for Shaily Engineering Plastics Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

1 of Shaily Engineering Plastics Limited's 18 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 15 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹2,985.1 +1.63% · +₹47.9

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance +21.3% 1Y

₹2.0k₹2.5k₹3.0k₹3.5kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 10 Nov 2025Q3 FY26 — 13 Feb 2026Q4 FY26 — 20 May 2026Q1 FY27 — 10 Aug 2026

1Y: ₹2,460.6 on 24 Oct 2025 → ₹2,985.1. High ₹3,457.9 (11 Aug 2026), low ₹1,821.6 (29 Jan 2026).

Previous close
₹2,937.2
Market cap
₹13.7k Cr
52-week range
₹1,821.6 – ₹3,457.9
One year
+17.54%
Price to earnings (TTM to Jun 2026)
78.01×
Return on equity (TTM to Jun 2026)
27.87%

Overview

Symbol
NSE:SHAILY
Industry
Consumer Discretionary
Exchange
NSE
Currency
INR

What Shaily Engineering Plastics Limited does

Based on the company's own presentations, annual report and earnings calls.

Shaily Engineering Plastics designs and manufactures precision injection-moulded plastic and metal components across three segments — Consumer, Industrial, and Healthcare — for OEM customers in India and over 35 export markets. Its Healthcare vertical makes drug-delivery devices such as pen injectors, auto-injectors, platform devices and pharma packaging, built around its own Shaily Harmony, Shaily Neo, Toby and Protean device platforms for GLP-1, insulin and other injectable therapies. The Consumer and Industrial businesses supply home-furnishing, FMCG-packaging, carbon-steel-furniture, LED-lighting, automotive, appliance and toy components. It runs mixed-material manufacturing (plastics plus steel) that lets a single facility serve a customer's full component set, supported by a UK-based innovation subsidiary, Shaily Innovations Limited, for design and drug-delivery R&D.

Segments

  • Healthcare
  • Consumer
  • Industrial
Manufacturing facilities
7 (Gujarat: 6 for plastics + 1 for steel furniture)
Injection moulding machines
200+, ranging 35–1,000 tons
Employees
2,000+
Export markets
35+ countries
Market position
India's largest exporter of plastics components
Global quality & compliance certifications
12, incl. ISO 9001, IATF 16949, ISO 13485, ISO 15378, MDSAP, ISO 14001, ISO 50001, RBA, AEO, ISCC Plus
Founded 1987Headquarters Vadodara, Gujarat, IndiaEmployees 2,000 (FY26) Company website

How the price took the results

close before → close after

Q1 FY27
+6.5%
10 Aug
Q4 FY26
+3.7%
20 May
Q3 FY26
−7.4%
13 Feb
Q2 FY26
−0.2%
10 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Shaily Engineering Plastics Limited

Free account: one company. Everything above stays public.

Write why you follow Shaily Engineering Plastics Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds